<DOC>
	<DOCNO>NCT00267150</DOCNO>
	<brief_summary>Treatment immunosuppressive drug mycophenolate mofetil ( MMF ) may result gastrointestinal ( GI ) complication patient . This study assess switch MMF enteric-coated mycophenolate sodium ( EC-MPS ) result improve GI and/or health-related quality life outcome determine proportion pancreas-kidney transplant recipient experience GI complaints MMF-based immunosuppressive treatment .</brief_summary>
	<brief_title>Gastrointestinal Health-related Quality Life Outcomes Patients With Simultaneous Pancreas-Kidney Transplants</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Received simultaneous pancreaskidney ( SPK ) transplant least 3 month prior study enrollment Receiving immunosuppressive regimen include MMF combination immunosuppressive drug ( i.e. , calcineurin inhibitor , mTOR inhibitor , steroid least three month time study enrollment ) Receiving MMF least 1 month prior enrollment ; maximal MMF dose 2000 mg/d . Patients know hypersensitivity mycophenolic acid , mycophenolate sodium , mycophenolate mofetil component formulation ( e.g . lactose ; see also SCP ECMPS ) If applicable , GI symptom assume know induced drug infection ( e.g . oral biphosphonates induce , infectious diarrhea ) Acute rejection &lt; 1 month prior study enrollment Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Simultaneous Pancreas-Kidney Transplantation</keyword>
	<keyword>mycophenolate</keyword>
	<keyword>GI problem</keyword>
</DOC>